The Goldman Sachs Group Increases Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price increased by The Goldman Sachs Group from $6.25 to $8.00 in a research note released on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also recently weighed in on the stock. Piper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an overweight rating in a research note on Thursday, March 21st. Truist Financial reaffirmed a buy rating and set a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday. StockNews.com downgraded shares of Amneal Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, March 4th. Finally, Barclays lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an overweight rating in a report on Monday, January 29th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of Buy and a consensus price target of $8.25.

Amneal Pharmaceuticals Trading Down 1.6 %

Shares of AMRX stock opened at $6.65 on Monday. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65. The firm’s 50 day moving average is $5.78 and its 200 day moving average is $5.32. Amneal Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $6.90.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million during the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. On average, equities analysts expect that Amneal Pharmaceuticals will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at about $39,000. Sherbrooke Park Advisers LLC purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $54,000. Trexquant Investment LP purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $65,000. TCG Advisory Services LLC purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $91,000. Finally, Aigen Investment Management LP bought a new position in Amneal Pharmaceuticals during the third quarter valued at $118,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.